<DOC>
	<DOC>NCT01893333</DOC>
	<brief_summary>To develope nerve sparing radical hysterectomy for treatment of cervical cancer to minimize the complication of radical hysterectomy and to maximize quality of life and to evaluate the feasibility and efficacy by prospective randomized trial.</brief_summary>
	<brief_title>The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Histologically diagnosed cervical cancer FIGO stage IA2IIA Diameter of tumor is less than 4cm on exam One of hitological type written below squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma Age between 1870 Performance status; GOG 01 Normal hematological, hepatic, nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥ 100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5 mg/dL SBOT/SGPT and Alkaline phoaphatase &lt; normal X 3 Patient with informed consent Exclusion creteria: Small cell carcinoma Unable to perform surgery because of severe underlying medical disease severe heart disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active bacterial infectio which needs non oral antibiotic therapy/ associated with other severe medical diseases Prior chemotherapy or radiotherapy Severe bladder funtion abnormality Double primary malignant tumor Psychiatric problems Pregnant or breast feeding status Legally unable to participate clinical trial When there is a Doctor's decision that patient is unable to participate clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>nerve sparing radical hysterectomy</keyword>
</DOC>